Publication|Videos|October 16, 2023
How to De-risk the Development of Highly Sensitive Injectables Using High-Performance Pre-fillable Syringe Systems
Author(s)Stevanato Group
Enrico Barichello, Product Manager for the Syringe Platform at Stevanato Group, discusses the risks associated with the interaction between primary packaging and complex novel therapeutics and describes how to prevent or manage concerns utilizing newer, pre-sterilized syringe systems that have more unique characteristics.
LEARN MORE IN THIS VIDEO:
- How Stevanato Group has responded to challenges pertaining to primary packaging of complex highly sensitive injectables
- Concerns with silicone and biopharmaceutical development
- Features of ALBA® technology for high-performance pre-fillable syringe systems
Related Content
Trending on Pharmaceutical Technology
1
Ask the Expert: Complying with Standards
2
Q&A: Why Sponsors Are Turning to Mixed FSP/FSO Models
3
How the Nitrosamine Guidance Shift is Changing LC-MS Workflows for APIs and Peptides
4
How Do CDMOs Scale High-Concentration Biologic Formulations?
5